A EuropaBio white paper calling for: equal assessment transparency; equal measures for traceability and adverse event reporting; and a level playing field for market access.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkLegal & Cookies